Switch theme
Sign up to access all valuation multiples
Senores Pharmaceuticals Ltd is a research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the Regulated Markets of the USA, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Its strength lies in identifying, developing and manufacturing a diverse range of specialty, underpenetrated and complex pharmaceutical products establishing the company as a preferred partner to certain customers. Through data analytics, research, market assessment and experienced management, It strategically identifies commercially underpenetrated molecules to launch products in the Regulated and Emerging Markets.
2017
145
LTM Revenue n/a
LTM EBITDA n/a
$324M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Senores Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Senores Pharmaceuticals achieved revenue of $24.5M and an EBITDA of $5.0M.
Senores Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Senores Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $4.1M | $24.5M | XXX | XXX | XXX |
| Gross Profit | $0.7M | $2.6M | XXX | XXX | XXX |
| Gross Margin | 17% | 11% | XXX | XXX | XXX |
| EBITDA | $1.9M | $5.0M | XXX | XXX | XXX |
| EBITDA Margin | 45% | 21% | XXX | XXX | XXX |
| Net Profit | $0.1M | $1.0M | XXX | XXX | XXX |
| Net Margin | 3% | 4% | XXX | XXX | XXX |
| Net Debt | $1.4M | $7.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Senores Pharmaceuticals's stock price is INR 553 (or $6).
Senores Pharmaceuticals has current market cap of INR 25.5B (or $296M), and EV of INR 27.9B (or $324M).
See Senores Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $324M | $296M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Senores Pharmaceuticals has market cap of $296M and EV of $324M.
Senores Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Senores Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Senores Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $324M | XXX | XXX | XXX |
| EV/Revenue | 13.2x | XXX | XXX | XXX |
| EV/EBITDA | 64.1x | XXX | XXX | XXX |
| P/E | 81.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -38.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSenores Pharmaceuticals's NTM/LTM revenue growth is n/a
Senores Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Senores Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Senores Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Senores Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 497% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 171% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 32% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Senores Pharmaceuticals acquired XXX companies to date.
Last acquisition by Senores Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Senores Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Senores Pharmaceuticals founded? | Senores Pharmaceuticals was founded in 2017. |
| Where is Senores Pharmaceuticals headquartered? | Senores Pharmaceuticals is headquartered in India. |
| How many employees does Senores Pharmaceuticals have? | As of today, Senores Pharmaceuticals has 145 employees. |
| Is Senores Pharmaceuticals publicy listed? | Yes, Senores Pharmaceuticals is a public company listed on NSE. |
| What is the stock symbol of Senores Pharmaceuticals? | Senores Pharmaceuticals trades under SENORES ticker. |
| When did Senores Pharmaceuticals go public? | Senores Pharmaceuticals went public in 2024. |
| Who are competitors of Senores Pharmaceuticals? | Similar companies to Senores Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Senores Pharmaceuticals? | Senores Pharmaceuticals's current market cap is $296M |
| What is the current revenue growth of Senores Pharmaceuticals? | Senores Pharmaceuticals revenue growth between 2023 and 2024 was 497%. |
| Is Senores Pharmaceuticals profitable? | Yes, Senores Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
